PIR and idiopathic pulmonary fibrosis: Pir was approved as the first therapy for mild and moderate IPF patients in the EU and USA as it has antioxidant, anti-inflammatory, and antifibrotic accomplishments (Tzouvelekis et al. 2017; Kreuter et al. 2021).